Spruce Street Capital LP Buys New Position in Enanta Pharmaceuticals, Inc. $ENTA

Spruce Street Capital LP bought a new stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 389,687 shares of the biotechnology company’s stock, valued at approximately $6,145,000. Enanta Pharmaceuticals accounts for 2.0% of Spruce Street Capital LP’s portfolio, making the stock its 20th biggest position. Spruce Street Capital LP owned 1.34% of Enanta Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Millennium Management LLC boosted its holdings in Enanta Pharmaceuticals by 50.2% during the 1st quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock valued at $7,435,000 after acquiring an additional 449,945 shares during the period. Marshall Wace LLP boosted its holdings in Enanta Pharmaceuticals by 0.8% during the 2nd quarter. Marshall Wace LLP now owns 857,412 shares of the biotechnology company’s stock valued at $6,482,000 after acquiring an additional 6,522 shares during the period. Commodore Capital LP acquired a new stake in Enanta Pharmaceuticals in the 3rd quarter valued at about $9,576,000. Geode Capital Management LLC boosted its stake in shares of Enanta Pharmaceuticals by 30.9% in the 4th quarter. Geode Capital Management LLC now owns 645,791 shares of the biotechnology company’s stock valued at $10,187,000 after buying an additional 152,597 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in shares of Enanta Pharmaceuticals by 33.9% in the 4th quarter. Renaissance Technologies LLC now owns 642,200 shares of the biotechnology company’s stock valued at $10,127,000 after buying an additional 162,600 shares during the period. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Stock Performance

Shares of NASDAQ ENTA opened at $11.44 on Tuesday. Enanta Pharmaceuticals, Inc. has a fifty-two week low of $6.43 and a fifty-two week high of $17.15. The firm has a market capitalization of $332.68 million, a PE ratio of -4.42 and a beta of 0.97. The stock’s 50-day simple moving average is $13.41 and its 200-day simple moving average is $13.70.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, May 11th. The biotechnology company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.01. Enanta Pharmaceuticals had a negative return on equity of 64.04% and a negative net margin of 89.56%.The business had revenue of $17.16 million for the quarter, compared to analyst estimates of $17.03 million. On average, sell-side analysts forecast that Enanta Pharmaceuticals, Inc. will post -1.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Wall Street Zen cut Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. Rodman & Renshaw assumed coverage on Enanta Pharmaceuticals in a research note on Thursday, March 26th. They issued a “buy” rating and a $20.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Monday, April 20th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $20.29.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.